Use of micro peptide miac

By discovering and applying micropeptide MIAC, the problems of heterogeneity of different tumor tissues and limited application of micropeptides are solved, effective inhibition and in vivo growth control of multiple tumor cells are achieved, and a wide range of applicable tumor treatment plans are provided.

WO2024235242A1PCT designated stage expired Publication Date: 2024-11-21NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/093260
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-15
Filing Date
2024-05-15
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

The genetic, phenotypic and immune heterogeneity of different tumor tissues makes the application of existing micropeptides in tumor treatment limited, and little is known about the research on multiple tumors, and there is a lack of effective diagnostic and treatment options.

Method used

A micropeptide MIAC has been discovered and prepared, and its amino acid sequence is MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG, used to prepare reagents or drugs for detecting, preventing or treating pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer and other tumors, and inhibiting tumor cells. Grow, migrate and proliferate.

Benefits of technology

MIAC is significantly low in tumor cells, and can effectively inhibit the proliferation and migration of a variety of tumor cells, especially the in vivo growth of hepatocellular carcinoma Hep3B cells, providing a wide range of applicable malignant tumor diagnosis and treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024093260_21112024_PF_FP_ABST
    Figure CN2024093260_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Use of a micro peptide MIAC, which belongs to the technical field of biomedicine. The present invention specifically relates to the use of the micro peptide MIAC in the preparation of a reagent or a drug for detecting, preventing or treating tumors. The tumors comprise one or more of solid tumors and hematologic malignancies, such as pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancies, myeloma, bile duct cancer and prostate cancer. The micro peptide MIAC has the effects of inhibiting the growth, proliferation and / or migration of various tumor cells, has a wide treatment spectrum, and is suitable for diagnosing, preventing or treating various tumors, specifically malignant tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Application of a micropeptide MIAC Technical Field

[0001] The present application belongs to the field of biomedicine technology, and specifically relates to the application of a micropeptide MIAC. Background Art

[0002] An open reading frame (ORF) is a potentially translatable sequence consisting of a string of in-frame sense codons that begins with a start codon and ends with a stop codon. Translatable ORFs are often labeled as coding DNA sequences (CDS) on mRNA, which are responsible for protein translation.

[0003] Long noncoding RNAs (lncRNAs) are noncoding RNAs greater than 200 nt in length. They are expressed in tissue- and development-specific ways and have been shown to directly regulate a variety of functions. LncRNAs also contain short open-reading frames (sORFs). These sORFs are generally less than 300 nt in length and were previously thought to lack coding capacity. However, recent studies have shown that some sORFs do have coding capacity, and their encoded products are defined as micropeptides.

[0004] From bacteria to humans, an increasing number of micropeptides of less than 150 amino acids have been discovered in various organisms. The functional diversity of these micropeptides and the emergence of new methods for their identification have attracted the attention of the scientific community. All these studies have shown that micropeptides translated from sORFs play important regulatory roles in many important physiological processes, such as muscle development, amino acid metabolism, immune regulation, tumor growth and cell death.

[0005] Maolei Zhang et al. discovered a lncRNA with potential coding capacity by performing circular RNA sequencing (circRNAseq) and ribosomal nascent peptide complex sequencing (RNC-seq) analysis on glioma cells. The experiment found that its second exon can form a circular RNA (circRNA) and be translated into an 87-amino acid micropeptide. In vitro and in vivo experiments showed that the micropeptide can inhibit the proliferation of gliomas and interact with the polymerase complex-associated factor PAF1 to inhibit the transcriptional elongation of multiple proto-oncogenes. Clinical sample analysis showed that compared with adjacent tissues, the micropeptide was significantly lower in breast cancer, liver cancer, and gastric cancer, suggesting its potential role in the diagnosis and treatment of malignant tumors (Zhang M, et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat Commun. 2018 Oct 26; 9(1): 4475.).

[0006] In related technologies, for example, the Chinese invention patent with publication number CN112442116A records the application of micropeptides encoded by lncRNA in the detection and treatment of malignant tumors such as head and neck cancer, thyroid cancer, and kidney cancer.

[0007] However, different tumor tissues have genetic, phenotypic and immune heterogeneity, and little is known about the research on micropeptides, including tumor treatment. It is necessary to explore their application in the treatment of different tumors. In order to further expand the spectrum of other tumors on which MIAC may play a role, the present invention attempts to detect the expression of MIAC in different tumor cells and corresponding normal cells, and uses in vitro and in vivo experimental systems to evaluate the activity of micropeptide MIAC in different tumors, providing a new solution for tumor treatment.

[0008] Summary of the Invention

[0009] 1. Purpose of the Invention

[0010] The purpose of the present invention is to provide an application of a micropeptide MIAC. After long-term exploration and continuous attempts, the inventors found that the micropeptide MIAC having the amino acid sequence shown in SEQ ID NO: 1 can be used to prepare reagents or drugs for detecting, preventing or treating tumors such as pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, prostate cancer, etc.

[0011] 2. Technical solution

[0012] In order to solve the above problems, the technical solutions adopted in this application are as follows:

[0013] The present application provides a use of a micropeptide MIAC in the preparation of an agent or drug for detecting, preventing or treating tumors. The micropeptide has an amino acid sequence as shown in SEQ ID NO: 1. The amino acid sequence of SEQ ID NO: 1 is: MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG.

[0014] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

[0015] Furthermore, the above-mentioned agent or drug for preventing or treating tumors contains at least the micropeptide MIAC with the amino acid sequence shown in SEQ ID NO: 1 and a pharmaceutically acceptable carrier.

[0016] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the growth, migration and / or proliferation of tumor cells.

[0017] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the proliferation of tumor cells.

[0018] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting tumor cell migration.

[0019] Furthermore, the above-mentioned prevention or treatment of tumors includes inhibiting the growth of tumor cells, especially the growth of tumor cells in the body.

[0020] Furthermore, the tumor cells inhibiting the proliferation of tumor cells include:

[0021] Pancreatic cancer cells include: any one or a combination of MIP-PaCa-2, Aspc-1, and PANC-1;

[0022] The liver cancer cells include: any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701 and Hep3B;

[0023] The colorectal cancer cells include: any one or a combination of LOVO, SW480 and HCT-116;

[0024] The ovarian cancer cells include: SKOV3 and / or A2780;

[0025] The cervical cancer cells include: Hela and / or SIHA;

[0026] The bladder cancer cells include: T24 and / or EJ;

[0027] The melanoma cancer cells include: any one or a combination of A375, SK-mel-2 and M14;

[0028] The glioblastoma cancer cells include: U87-MG;

[0029] The neuroblastoma cancer cells include: SH-SY5Y;

[0030] The glioma cancer cells include: SHG-44;

[0031] The osteosarcoma cancer cells include: any one or a combination of MG-63, Saos-2 and U-2OS;

[0032] The lymphoma cancer cells include: any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10 and JeKo-1;

[0033] The hematological tumor cancer cells include: any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60;

[0034] The myeloma cancer cells include: any one or a combination of NCI-H929, ARP-1 and RPMI-8226;

[0035] The bile duct cancer cell line includes: QBC939;

[0036] and / or,

[0037] The prostate cancer cells include Du145 cells.

[0038] Furthermore, the tumor cells inhibiting tumor cell migration include: prostate cancer Du145 cells, cervical cancer Hela cells, osteosarcoma MG-63 cells, ovarian cancer SKOV3 cells, melanoma A375 cells and / or liver cancer Hep3B cells.

[0039] Furthermore, the tumor cells inhibiting tumor cell growth include: liver cancer Hep3B cells.

[0040] The present application also provides the use of a nucleotide encoding the amino acid sequence shown in SEQ ID NO: 1 in the preparation of an agent or drug for detecting, preventing or treating tumors.

[0041] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

[0042] Furthermore, the nucleotide sequence comprises the nucleotide sequence shown in SEQ ID NO: 2, and the nucleotide sequence shown in SEQ ID NO: 2 is: atggagagagcaggggtgcccgggttctctccgcggcgctcatcggtggaggcgaagatgcagagcaccagctgcagtgtcaggaagagctccacagtcaccgcctggccagccgtcgtgctgttgctgagctggggacagagaagaggcggatga.

[0043] The present application also provides a use of a recombinant vector in preparing a tumor reagent or drug for detecting, preventing or treating tumors, wherein the recombinant vector encodes the amino acid sequence shown in SEQ ID NO: 1 or contains the nucleotide sequence shown in SEQ ID NO: 2.

[0044] Furthermore, the above-mentioned tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

[0045] A pharmaceutical composition for treating tumors, comprising at least the above-mentioned micropeptide MIAC, the above-mentioned nucleotide, or the above-mentioned recombinant vector, and a pharmaceutically acceptable carrier, wherein the tumors include one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

[0046] The present application also provides a method for detecting, preventing or treating tumors, which comprises administering a micropeptide MIAC comprising the amino acid sequence shown in SEQ ID NO: 1, or a pharmaceutical composition comprising the micropeptide MIAC, to a subject in need thereof.

[0047] Furthermore, the above-mentioned subjects can be humans, mice, or monkeys.

[0048] Furthermore, in the above method, 0.1-50 mg / kg, 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 5-20 mg / kg, 10-20 mg / kg or 5-15 mg / kg of the micropeptide MIAC is administered to the subject.

[0049] 3. Beneficial effects

[0050] Compared with the prior art, the present application has the following advantages:

[0051] (1) The expression level of the micropeptide MIAC provided in this application in human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer cells is significantly lower than that in the corresponding normal cells.

[0052] (2) The application of the micropeptide MIAC provided in the present application can significantly inhibit the proliferation of tumor cells of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematology, myeloma, and bile duct cancer, as well as inhibit the migration of tumor cells of prostate cancer, cervical cancer, osteosarcoma, ovarian cancer, melanoma, and liver cancer.

[0053] (3) The application of the micropeptide MIAC provided in this application can significantly inhibit the in vivo growth of liver cancer, especially liver cancer Hep3B cells.

[0054] (4) The micropeptide MIAC provided in this application has the effect of inhibiting the proliferation and migration of various tumor cells, as well as the tumor growth of liver cancer in vivo. It has a wide therapeutic spectrum and is suitable for the diagnosis, prevention or treatment of various tumors, especially malignant tumors. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1 is the expression analysis results of the micropeptide MIAC in different tumor cells and normal cells;

[0056] Figure 2A is the statistical results of the inhibition of the migration activity of prostate cancer Du145 cells by micropeptide MIAC;

[0057] FIG2B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of prostate cancer Du145 cells;

[0058] FIG3A is the statistical result of the micropeptide MIAC inhibiting the migration activity of cervical cancer Hela cells;

[0059] FIG3B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of cervical cancer Hela cells;

[0060] FIG4A is the statistical result of the inhibition of the migration activity of osteosarcoma MG-63 cells by micropeptide MIAC;

[0061] FIG4B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of osteosarcoma MG-63 cells;

[0062] FIG5A is the statistical result of the micropeptide MIAC inhibiting the migration activity of ovarian cancer SKOV3 cells;

[0063] FIG5B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of ovarian cancer SKOV3 cells;

[0064] FIG6A is the statistical result of the micropeptide MIAC inhibiting the migration activity of malignant melanoma A375 cells;

[0065] FIG6B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of malignant melanoma A375 cells;

[0066] FIG7A is the statistical result of the inhibition of Hep3B cell migration by micropeptide MIAC;

[0067] FIG7B is a cell staining diagram of the blank group and each drug-treated group in the micropeptide MIAC inhibition activity test of liver cancer Hep3B cells;

[0068] FIG8 is a graph showing the in vivo growth curve of MIAC inhibiting subcutaneous transplanted tumors of Hep3B cells in nude mice in Example 4;

[0069] FIG9 is a statistical graph showing the effect of MIAC on the tumor weight of nude mice subcutaneously transplanted with liver cancer Hep3B cells on day 22 in Example 4. DETAILED DESCRIPTION

[0070] The present application is further described below with reference to specific embodiments.

[0071] It should be noted that the terms such as "upper", "lower", "left", "right", and "middle" cited in this specification are only for the convenience of description and are not used to limit the scope of implementation. Changes or adjustments to their relative relationships should be regarded as the scope of implementation of this application without substantially changing the technical content.

[0072] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.

[0073] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or those recommended by the manufacturer. All reagents or instruments used, if the manufacturer is not specified, are commercially available conventional products.

[0074] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement, or value. One skilled in the art can readily determine the degree of flexibility for a particular variable.

[0075] As used herein, the term "at least one of" is intended to be synonymous with "one or more of." For example, "at least one of A, B, and C" explicitly includes only A, only B, only C, and combinations of each thereof.

[0076] Concentration, amount and other numerical data can be presented in range format in this article.Should be understood that such range format is only used for convenience and brevity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all independent numerical values ​​or subranges encompassed within the scope, just as each numerical value and subrange are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including independent numerals (such as 2,3,4) and subranges (such as 1 to 3,2 to 4 etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all above-mentioned values ​​and scopes.In addition, no matter how the breadth of described scope or feature is, this explanation should be applicable.

[0077] Micropeptide Inhibiting Actin Cytoskeleton (MIAC) is a human endogenous protein or polypeptide fragment with 51 amino acids encoded by non-coding RNA (lncRNA). The micropeptide MIAC has the amino acid sequence: MERAGVPGFSPRRSSVEAKMQSTSCSVRKSSTVTAWPAVVLLLSWGQRRGG (SEQ ID NO: 1).

[0078] The present application provides the use of the above-mentioned micropeptide MIAC in the preparation of reagents or drugs for detecting, preventing or treating tumor diseases.

[0079] In some embodiments, the tumor comprises a solid tumor or a hematological tumor.

[0080] In some embodiments, the tumor comprises pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and / or prostate cancer.

[0081] The micropeptide MIAC provided in the present application has the effect of inhibiting the growth, migration and / or proliferation of tumor cells in vivo and / or in vitro.

[0082] In some embodiments, the micropeptide MIAC has an inhibitory effect on the proliferation of various tumor cells including:

[0083] Pancreatic cancer cells, comprising: any one or a combination of MIP-PaCa-2, Aspc-1, and PANC-1;

[0084] Liver cancer cells, including any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701, and Hep3B;

[0085] Colorectal cancer cancer cells, including: any one or a combination of LOVO, SW480, and HCT-116;

[0086] Ovarian cancer cells, including: SKOV3 and / or A2780;

[0087] Cervical cancer cells, including HeLa and / or SIHA;

[0088] Bladder cancer cells, including: T24 and / or EJ;

[0089] Melanoma cancer cells, including any one or a combination of A375, SK-mel-2, and M14;

[0090] Glioblastoma cancer cells, including: U87-MG;

[0091] In neuroblastoma, cancer cells include: SH-SY5Y;

[0092] Glioma cancer cells, including: SHG-44;

[0093] Osteosarcoma cancer cells, including any one or a combination of MG-63, Saos-2, and U-2OS;

[0094] Lymphoma cancer cells, including any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10, and JeKo-1;

[0095] Hematological cancer cells, including any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60;

[0096] Myeloma cancer cells, including any one or a combination of NCI-H929, ARP-1, and RPMI-8226;

[0097] Cholangiocarcinoma cancer cells, including: QBC939;

[0098] Prostate cancer cells, including Du145 cells.

[0099] The micropeptide MIAC provided in the present application has the effect of inhibiting tumor cell proliferation in the ranges of 50-200 μM, 10-200 μM, and 50-100 μM.

[0100] In some embodiments, the micropeptide MIAC can also inhibit the migration of tumor cells, specifically including: human prostate cancer Du145 cells, human cervical cancer Hela cells, human osteosarcoma MG-63 cells, human ovarian cancer SKOV3 cells, human malignant melanoma A375 cells and / or human liver cancer Hep3B cells.

[0101] Optionally, the micropeptide MIAC can inhibit tumor cell migration within the range of 0.78-50 μM, 0.78-25 μM, 1.56-50 μM, 3.125-50 μM, 6.25-50 μM, 25-50 μM or 12.5-50 μM.

[0102] The micropeptide MIAC provided herein can inhibit the in vivo growth of tumor cells. Alternatively, MIAC can inhibit the in vivo tumor growth of human liver cancer cells. In some embodiments, the micropeptide MIAC inhibits the in vivo tumor growth of liver cancer Hep3B cells.

[0103] Therefore, the present application also provides a method for detecting, preventing or treating tumor diseases, which comprises administering to a subject in need thereof a micropeptide MIAC comprising or having the amino acid sequence shown in SEQ ID NO: 1, or a pharmaceutical composition comprising the micropeptide MIAC.

[0104] The subject can be selected from humans, mice, monkeys, dogs, and pigs. In some embodiments, the subject is humans, monkeys, dogs, or mice.

[0105] When a pharmaceutical composition comprising the micropeptide MIAC is administered to a subject, the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.

[0106] The term "pharmaceutically acceptable carrier" refers to an excipient or carrier that does not cause significant irritation to the subject and does not abrogate the biological activity and properties of the administered anti-mesothelin antibody or antigen-binding fragment thereof and / or any additional therapeutic agent in the composition. A pharmaceutically acceptable carrier can enhance or stabilize the composition or can be used to facilitate its preparation.

[0107] The pharmaceutical composition comprising the micropeptide MIAC can be selected according to the specific applicable form, physicochemical characteristics, etc. of a pharmaceutically acceptable carrier, and a suitable mode of administration can be selected. In some embodiments, the pharmaceutical composition can be formed into a preparation in the form of a freeze-dried preparation or a liquid preparation, and the preparation can contain appropriate preparation additives in the art. For example, in the above-mentioned pharmaceutical composition, typically, more than one pharmaceutical excipient is contained, such as a sterilized liquid, such as water and oil (including oils of petroleum, animal, plant, or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.)). In the case of intravenous administration of the above-mentioned pharmaceutical composition, water is a more representative carrier. In addition, saline solution, as well as glucose aqueous solution and glycerol aqueous solution can also be used as liquid carriers, especially for injectable solutions. Suitable pharmaceutical excipients are known in the art. As needed, the composition can also contain a trace of wetting agent or emulsifier or pH buffering agent. The pharmaceutical composition is usually administered parenterally, which may be intradermal, intramuscular, intraperitoneal, intravenous or subcutaneous injection, but is not limited thereto. For example, it may be administered by infusion or bolus injection, intracranial, intrathecal or intranasal (e.g., inhalation), intradermal, subcutaneous or transmucosal administration.

[0108] When using micropeptide MIAC to detect, prevent or treat tumors, the dosage is varied according to the specific condition being treated, the severity of the condition, individual patient parameters (including age, physical condition, size, sex and weight), duration of treatment, the nature of concurrent therapy (if any), the specific route of administration, and the knowledge of the physician or veterinarian, and the dosage is gradually increased until the desired effect is achieved. In some embodiments, the dosage of the active ingredient can be determined empirically in individuals who have been given one or more micropeptide MIAC administrations.

[0109] In some embodiments, for example, when 0.1-50 mg / kg, 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 5-20 mg / kg, 10-20 mg / kg or 5-15 mg / kg of the micropeptide MIAC is administered to a subject, the tumorigenicity of tumor cells can be significantly inhibited, in particular, the tumorigenicity of tumor cells in vivo can be inhibited.

[0110] In some embodiments, the dose administered to the subject can be converted between species, such as between humans and mice. Such conversion methods are known in the art, see, for example, Xu Shuyun, Pharmacological Experimental Methodology, 2nd edition [M]. People's Medical Publishing House, 1991, the contents of each of which are hereby incorporated herein by reference.

[0111] The technical solutions of the present invention will be more clearly and specifically described below in conjunction with the examples in an illustrative manner. It should be understood that these examples are for illustrative purposes only and are in no way intended to limit the scope of protection of the present invention. The scope of protection of the present invention is defined solely by the claims.

[0112] Example 1

[0113] This example detects the expression of the micropeptide MIAC in different tumor cells and normal cells.

[0114] (1) Cell culture and RNA extraction

[0115] Human pancreatic ductal epithelial cells HPDE, pancreatic cancer cells PANC-1, Aspc-1; human normal liver cells L02, liver cancer cells HepG2, QGY-7701, Hep3B; human normal colon cells CCD-18Co, colorectal cancer cells SW480, HCT-116; human normal ovarian epithelial cells IOSE-80, ovarian cancer cells SKOV3, A2780; human cervical epithelial cells HCerEpiC, cervical cancer cells Hela, SIHA; human normal bladder epithelial cells SV-HUC-1, bladder cancer cells T24, EJ; human epidermal keratinocytes HEKa, melanocytes SK-mel-2, M14; human brain glial cells T98G, glial Tumor cells SHG-44, neuroblastoma cells SH-SY5Y; human osteoblast cell line hFOB1.19, osteosarcoma cells MG-63, U-2OS; human T lymphocytes H9, lymphoma cells U2932, WSU-DLCL2, JeKo-1; human peripheral blood mononuclear cells PBMC, hematological malignancy cells K562, HL60, NCI-H929, RPMI-8226; human intrahepatic bile duct epithelial cells HIBEpiC, cholangiocarcinoma cells QBC939; human prostate epithelial cells HPEpiC and prostate cancer cells Du145 were cultured in a 37°C, 5% CO2 incubator to a density of 90%. The supernatant was discarded, a certain volume of Trizol (Life Invitrogen) was added, and total RNA from different cells was extracted according to the manufacturer's instructions.

[0116] (2) Primer design

[0117] Primers were designed based on the nucleotide sequence information encoding the micropeptide MIAC, and the sequences are as follows:

[0118] Upstream primer (SEQ ID NO. 3): ATGGAGAGAGCAGGGGTGCCCG;

[0119] Downstream primer (SEQ ID NO. 4): CGCCTCTTCTCTGTCCCCAGCTC.

[0120] (3) Real-time quantitative PCR was used to detect the expression of micropeptide MIAC in different tumor cells and normal cells.

[0121] The total RNA extracted in the above steps was quantified using a NanoDrop ND-1000 nucleic acid quantifier to determine the purity and concentration of the extracted RNA. Agarose gel quality control was performed to ensure the integrity of the extracted RNA. The extracted total RNA was reverse transcribed into cDNA using the TaKaRa kit PrimeScriptTM RT reagent Kit with gDNA Eraser (Perfect Real Time). Premix Ex Taq TM qPCR was performed with Tli RNase H Plus. The reaction system is shown in Table 1. The above components were mixed and the following protocol was used: pre-denaturation at 95°C for 30 s, 40 cycles of denaturation at 95°C for 5 s, and 60°C for 30 s.

[0122] Table 1 PCR reaction system

[0123] The specificity of the reaction was determined based on the melting curves, and the relative expression of MIAC was calculated using the formula 2-ΔΔCt. The results are shown in Figure 1. Compared with corresponding normal cells, MIAC expression levels were significantly lower in human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, myeloma, lymphoma, hematologic malignancy, and cholangiocarcinoma cells than in normal cells. Therefore, the anti-tumor effect of MIAC was subsequently investigated in these tumor cells.

[0124] Example 2

[0125] This example provides the inhibitory effect of the micropeptide MIAC on the proliferation of human tumor cells.

[0126] Human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, myeloma, lymphoma, hematologic malignancy, and bile duct cancer cells were cultured in an incubator at 37°C and 5% CO2 until the density reached 90%. The cells were then digested and collected using trypsin. The cells were resuspended in culture medium and counted under a microscope to adjust the cell concentration to approximately 1.0 × 10 5Cells were plated in a 96-well plate at a concentration of 100 μL per well at 37°C (5% CO₂) per mL. The cells were cultured overnight in a 37°C, 5% CO₂ incubator. After complete cell attachment, 100 μL of MIAC at concentrations of 50 μM, 100 μM, or 200 μM was added to the treatment group; a negative control group was maintained without any drug. After 72 hours of incubation, 100 μL of CCK8 was added to each well of the 96-well plate. The absorbance (OD) was measured at a wavelength of 450 nm using a microplate reader, and the growth inhibition rate (PI) was calculated using the formula: PI (%) = 1 treatment group / negative control group. The experiment was repeated three times, and the results are expressed as mean ± SD. T-tests were performed. *P < 0.05 indicates a significant difference, and **P < 0.01 indicates a highly significant difference. The results are shown in Tables 2-52.

[0127] Table 2 Inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cells PANC-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0128] Table 3 Inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cell Aspc-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0129] Table 4 Inhibitory effect of micropeptide MIAC on the proliferation of human pancreatic cancer cells MIP-PaCa-2 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0130] Table 5 Inhibitory effect of micropeptide MIAC on the proliferation of human esophageal cancer cell Eca-109 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0131] Table 6 Inhibitory effect of micropeptide MIAC on proliferation of human esophageal cancer cell line CaES-17 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0132] Table 7 Inhibitory effect of micropeptide MIAC on the proliferation of human gastric cancer cell BGC-803 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0133] Table 8 Inhibitory effect of micropeptide MIAC on the proliferation of human gastric cancer cell BGC-823 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0134] Table 9 Inhibitory effect of micropeptide MIAC on proliferation of human liver cancer cells HepG2 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0135] Table 10 Micropeptide MIAC inhibits proliferation of human hepatocellular carcinoma cell line SMMC-7721 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0136] Table 11 Micropeptide MIAC inhibits proliferation of human hepatocellular carcinoma cell line HCCLM3 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0137] Table 12 Micropeptide MIAC inhibits proliferation of human liver cancer cell QGY-7701 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0138] Table 13 Micropeptide MIAC inhibits proliferation of human colon cancer cells LOVO Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0139] Table 14 Inhibitory effect of micropeptide MIAC on proliferation of human colon cancer cell line SW480 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0140] Table 15 Micropeptide MIAC inhibits proliferation of human colon cancer cells HCT-116 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0141] Table 16 Micropeptide MIAC inhibits proliferation of human breast cancer cells MX-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0142] Table 17 Micropeptide MIAC inhibits proliferation of human breast cancer cells MDA-MB-231 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0143] Table 18 Micropeptide MIAC inhibits proliferation of human breast cancer cells MCF-7 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0144] Table 19 Micropeptide MIAC inhibits proliferation of human ovarian cancer cell SKOV3 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0145] Table 20 Micropeptide MIAC inhibits proliferation of human ovarian cancer cell A2780 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0146] Table 21 Micropeptide MIAC inhibits proliferation of human cervical cancer cells Hela Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0147] Table 22 Micropeptide MIAC inhibits proliferation of human cervical cancer cell SIHA Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0148] Table 23 Micropeptide MIAC inhibits proliferation of human non-small cell lung cancer cells NCI-H1299 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0149] Table 24 Micropeptide MIAC inhibits proliferation of human non-small cell lung cancer cells NCI-H1650 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0150] Table 25 Micropeptide MIAC inhibits proliferation of human lung giant cell carcinoma cell line 95-D Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0151] Table 26 Micropeptide MIAC inhibits proliferation of human bladder transitional cell carcinoma cell T24 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0152] Table 27 Micropeptide MIAC inhibits proliferation of human bladder cancer cells EJ Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0153] Table 28 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells A375 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0154] Table 29 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells SK-mel-2 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0155] Table 30 Micropeptide MIAC inhibits proliferation of human malignant melanoma cells M14 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0156] Table 31 Micropeptide MIAC inhibits the proliferation of human brain glioblastoma cells U87-MG Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0157] Table 32 Micropeptide MIAC inhibits proliferation of human neuroblastoma cells SH-SY5Y Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0158] Table 33 Micropeptide MIAC inhibits proliferation of human glioma cells SHG-44 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0159] Table 34 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells MG-63 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0160] Table 35 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells Saos-2 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0161] Table 36 Micropeptide MIAC inhibits proliferation of human osteosarcoma cells U-2OS Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0162] Table 37 Micropeptide MIAC inhibits proliferation of human histiocytic lymphoma cells U937 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0163] Table 38 Micropeptide MIAC inhibits proliferation of human lymphoma cells Raji Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0164] Table 39 Micropeptide MIAC inhibits proliferation of human diffuse large B lymphoma cells U2932 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0165] Table 40 Micropeptide MIAC inhibits proliferation of human diffuse large B lymphoma cells WSU-DLCL2 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0166] Table 41 Micropeptide MIAC inhibits proliferation of human diffuse large B lymphoma cells OCI-LY10 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0167] Table 42 Micropeptide MIAC inhibits proliferation of human mantle cell lymphoma cells JeKo-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0168] Table 43 Micropeptide MIAC inhibits proliferation of human acute promyelocytic leukemia cells NB4 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0169] Table 44 Micropeptide MIAC inhibits the proliferation of human acute non-T non-B lymphocytic leukemia cells Reh Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0170] Table 45 Micropeptide MIAC inhibits proliferation of human chronic myeloid leukemia cells K562 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0171] Table 46 Micropeptide MIAC inhibits proliferation of human monocytic leukemia cells Thp-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0172] Table 47 Micropeptide MIAC inhibits the proliferation of human T lymphoma leukemia cells JurKat Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0173] Table 48 Micropeptide MIAC inhibits proliferation of human myeloid leukemia cells HL60 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0174] Table 49 Micropeptide MIAC inhibits proliferation of human myeloma cells NCI-H929 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0175] Table 50 Micropeptide MIAC inhibits the proliferation of human myeloma cells ARP-1 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0176] Table 51 Micropeptide MIAC inhibits proliferation of human multiple myeloma peripheral blood B lymphocytes RPMI-8226 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0177] Table 52 Micropeptide MIAC inhibits proliferation of human bile duct cancer cell QBC939 Note: Compared with the negative control group, *P<0.05, **P<0.01.

[0178] As can be seen from Table 2-52, compared with the negative control, at a dose of 50 to 200 μM, the micropeptide MIAC can significantly inhibit the proliferation of human pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioma, neuroblastoma, osteosarcoma, myeloma, lymphoma, leukemia, and bile duct cancer cells to varying degrees, and shows a dose-dependent relationship.

[0179] Example 3

[0180] This example provides the inhibitory effect of the micropeptide MIAC on the migration of human tumor cells.

[0181] Human prostate cancer, cervical cancer, osteosarcoma, ovarian cancer, melanoma, and liver cancer cells were inoculated into transwell chambers, with 100 μL per well. 100 μL of micropeptide MIAC at different doses was added to each chamber as the drug-dosing group, and no drug was added to the blank group. Then 0.6 mL of complete culture medium containing 10% FBS was added to the lower chamber of the transwell to stimulate cell migration, and the cells were cultured at 5% CO2 and 37°C for 48 hours. The culture medium in the wells was discarded, the cells were fixed with methanol at room temperature for 30 minutes, stained with 0.1% crystal violet at room temperature for 10 minutes, rinsed with clean water, and the unmigrated cells on the upper layer were wiped off with a cotton swab. The cells were observed under a microscope and four fields of view were selected for photographing and counting. The migration inhibition rate (MI) was calculated according to the formula:

[0182] Among them, N test is the number of cell migration in the drug-treated group, N control is the number of migrated cells in the blank control group.

[0183] The results are shown in Tables 53-58 and Figures 2-7.

[0184] Table 53 Inhibitory effect of MIAC on the migration activity of prostate cancer Du145 cells

[0185] Figure 2A corresponds to the statistical graphs of each group in Table 53; Figure 2B corresponds to the staining images of each group of cells in the above Table 53.

[0186] Table 54 Inhibitory effect of MIAC on the migration activity of cervical cancer Hela cells

[0187] Figure 3A corresponds to the statistical graphs of each group in Table 54; Figure 3B corresponds to the staining images of each group of cells in the above Table 54.

[0188] Table 55 Inhibitory effect of MIAC on the migration activity of osteosarcoma MG-63 cells

[0189] Figure 4A corresponds to the statistical graphs of each group in Table 55; Figure 4B corresponds to the staining images of each group of cells in the above Table 55.

[0190] Table 56 Inhibitory effect of MIAC on the migration activity of ovarian cancer SKOV3 cells

[0191] Figure 5A corresponds to the statistical graphs of each group in Table 56; Figure 5B corresponds to the staining images of each group of cells in the above Table 56.

[0192] Table 57 Inhibitory effect of MIAC on the migration activity of malignant melanoma A375 cells

[0193] Figure 6A corresponds to the statistical graphs of each group in Table 57; Figure 6B corresponds to the staining images of each group of cells in the above Table 57.

[0194] Table 58 Inhibitory effect of MIAC on the migration activity of liver cancer Hep3B cells

[0195] Figure 7A corresponds to the statistical graphs of each group in Table 58; Figure 7B corresponds to the staining images of each group of cells in the above Table 58.

[0196] It can be seen from Tables 53-58 and Figures 2-7 that compared with the blank control, the micropeptide MIAC has a significant inhibitory effect on the migration of human prostate cancer Du145 cells, human osteosarcoma MG-63 cells, human ovarian cancer SKOV3 cells, human liver cancer Hep3B cells, human melanoma A375 cells, and human cervical cancer Hela cells within a certain range, and the inhibition rate is dose-dependent, indicating that the micropeptide MIAC can be developed into an anti-tumor drug by inhibiting the migration of the above-mentioned malignant tumor cells.

[0197] Example 4

[0198] This example provides the inhibitory effect of the micropeptide MIAC on the growth of human tumor cells in vivo.

[0199] Human hepatoma cell line Hep3B was cultured in large quantities and digested with 0.25% trypsin solution. After digestion, the cell suspension was centrifuged at 1000 rpm for 5 min. The cells were resuspended in serum-free MEM medium and counted. The cell concentration was adjusted to 5 × 10 7 Each BALB / c nude mouse (46-week-old female, weighing 1416 g, acclimatized in an SPF animal breeding room for 1 week) was inoculated with 100 μL of cell suspension in the left axilla, with an injection volume of 5×10 6 After inoculation, the nude mice were closely observed for tumor growth at the inoculation site. On the 7th day after inoculation, a white nodule appeared at the inoculation site, which could be moved subcutaneously after being touched. As the tumor tissue grew, a hard tumor mass gradually formed at the inoculation site. After about 14 days, the average volume of the tumor tissue reached 100 mm. 3 BALB / c nude mice were randomly divided into 7 groups (normal saline group as blank control, micropeptide MIAC dosage of 5mg / kg as low dose, micropeptide MIAC dosage of 10mg / kg as medium dose, micropeptide MIAC dosage of 15mg / kg as medium-high dose, micropeptide MIAC dosage of 20mg / kg as high dose, oxaliplatin 15mg / kg and sorafenib 50mg / kg as positive control), 10 mice in blank group and 6 mice in each of the other groups. The weight of the animals was about 20g when the drug was started. The transplanted tumor volume was measured and recorded every two days. The tumor volume (TV) was calculated as follows: Tumor volume = 0.5×a×b 2 , where a is the length of the transplanted tumor (mm) and b is the width of the transplanted tumor (mm).

[0200] The results are shown in Figures 8 and 9. Compared with the blank control group, the micropeptide MIAC was able to significantly inhibit the in vivo tumor growth of human liver cancer cell Hep3B to varying degrees, and in a dose-dependent manner. At a dose of 20 mg / kg, the therapeutic effect on tumors was similar to that of positive drugs, indicating that the micropeptide MIAC has a strong anti-tumor effect in vivo.

Claims

1. Use of a micropeptide MIAC in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The micropeptide MIAC has an amino acid sequence as shown in SEQ ID NO: 1; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

2. The use of a micropeptide MIAC according to claim 1 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The agent or drug for preventing or treating tumors contains at least micropeptide MIAC and a pharmaceutically acceptable carrier.

3. Use of a micropeptide MIAC according to claim 1 or 2 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The prevention or treatment of tumors includes inhibiting the growth, migration and / or proliferation of tumor cells.

4. The use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The prevention or treatment of tumors includes: inhibiting the proliferation of tumor cells, The pancreatic cancer cells include: any one or a combination of MIP-PaCa-2, Aspc-1 and PANC-1; The liver cancer cells include: any one or a combination of HepG2, SMMC-7721, HCCLM3, QGY-7701 and Hep3B; The colorectal cancer cells include: any one or a combination of LOVO, SW480 and HCT-116; The ovarian cancer cancer cells include: SKOV3 and / or A2780; The cancer cells of cervical cancer include: Hela and / or SIHA; The bladder cancer cancer cells include: T24 and / or EJ; The melanoma cancer cells include: any one or a combination of A375, SK-mel-2 and M14; The glioblastoma cancer cells include: U87-MG; The neuroblastoma cancer cells include: SH-SY5Y; The glioma cancer cells include: SHG-44; The osteosarcoma cancer cells include: any one or a combination of MG-63, Saos-2 and U-2OS; The lymphoma cancer cells include: any one or a combination of U937, Raji, U2932, WSU-DLCL2, OCI-LY10 and JeKo-1; The cancer cells of the blood tumor include: any one or a combination of NB4, Reh, K562, Thp-1, JurKat and HL60; The myeloma cancer cells include: any one or a combination of NCI-H929, ARP-1 and RPMI-8226; The cholangiocarcinoma cancer cells include: QBC939; and / or, The prostate cancer cells include: Du145 cells.

5. Use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The tumor prevention or treatment comprises: inhibiting the migration of prostate cancer Du145 cells, cervical cancer Hela cells, osteosarcoma MG-63 cells, ovarian cancer SKOV3 cells, melanoma A375 cells and / or liver cancer Hep3B cells.

6. Use of a micropeptide MIAC according to claim 3 in the preparation of an agent or drug for detecting, preventing or treating tumors, characterized in that: The tumor prevention or treatment includes: inhibiting the growth of liver cancer Hep3B cells.

7. Use of a nucleotide in the preparation of a reagent or drug for detecting, preventing or treating a tumor, characterized in that: The nucleotide encodes the amino acid sequence shown in SEQ ID NO: 1; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

8. Use of a nucleotide according to claim 7 in the preparation of a reagent or drug for detecting, preventing or treating tumors, characterized in that: The nucleotide sequence comprises the nucleotide sequence shown in SEQ ID NO:

2.

9. Use of a recombinant vector in the preparation of an agent or drug for detecting, preventing or treating a tumor, characterized in that: The recombinant vector encodes the amino acid sequence shown in SEQ ID NO: 1 or contains the nucleotide sequence shown in SEQ ID NO: 2; the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

10. A pharmaceutical composition for treating tumors, characterized in that: The pharmaceutical composition contains at least the micropeptide MIAC according to claim 1, the nucleotide according to claim 7 or 8, or the recombinant vector according to claim 9, and a pharmaceutically acceptable carrier, and the tumor includes one or more of pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, bladder cancer, melanoma, glioblastoma, neuroblastoma, glioma, osteosarcoma, lymphoma, hematologic malignancy, myeloma, bile duct cancer, and prostate cancer.

Citation Information

Patent Citations

  • Application of micro peptide CIP2A-BP in treatment of cancer

    CN110064045A

  • Application of micropeptide ASRPS in treating cancer

    CN110215511A

  • Novel micro-peptide HMMW and application thereof

    CN112442116A

  • Long-chain non-coding RNA RP11-469H8.6 and application thereof

    CN112442537A

  • Micropeptides and uses thereof

    US20210017242A1